KRAS G13D in mCRC — historical signal of partial cetuximab response (De Roock 2010) was n...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G13D-CRC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CRC |
| Sources | SRC-CIVIC SRC-NCCN-COLON-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | KRAS G13D |
| Disease | DIS-CRC |
| ESCAT tier | IV |
| Evidence summary | KRAS G13D in mCRC — historical signal of partial cetuximab response (De Roock 2010) was not confirmed prospectively. Treat as RAS-mut, anti-EGFR contraindicated. |
Notes
ESCAT IV. Encoded under BIO-RAS-MUTATION (no variant-specific BIO for KRAS G13D yet). FLAG: dedicated BIO-KRAS-G13D would improve granularity.
Used By
No reverse references found in the YAML corpus.